In 2017, The Max Foundation and Fred Hutchinson Cancer Research Center (Fred Hutch) embarked on a groundbreaking collaboration to increase access to testing for chronic myeloid leukemia (CML) patients in under-resourced countries.
The collaboration is called Spot On CML and utilizes a special process developed by Fred Hutch researcher and The Max Foundation board member Dr. Jerry Radich. In it, paper test cards are spotted with dried blood samples and mailed to Fred Hutch from all over the world, where researchers perform testing on the samples free-of-charge.
Today, Spot On CML is active in 19 countries and, on June 29th, 17 patients were chosen by the treating physicians at Philippine General Hospital to take part in the program. While CML testing is available in the Philippines, it’s prohibitively expensive – placing critical diagnostic information out of reach for many patients.
The patients, the treating physicians at Philippine General, and the team at The Max Foundation all offer their heartfelt gratitude to Fred Hutch for this wonderful collaboration.
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
The Max Foundation and Cepheid have renewed and expanded their collaboration to increase access to molecular diagnostics in low- and middle-income countries (LMICs).
Now in its 20th year, The Max Foundation is undergoing exciting strategic changes aimed at strengthening organizational efforts to improve global access to cancer treatment, care and support. To that end, we announce the launch of MaxAid, a subsidiary organization set up by The Max Foundation to further its mission. MaxAid is a Washington nonprofit corporation with its own IRS determination letter of 501(c)(3) public charity status.
The Max Foundation to launch its Max Access Solutions program for patients with HR+/HER2- advanced breast cancer in collaboration with leading oncologists in low- and middle-income countries (LMICs) and the ABC Global Alliance, the American Society for Clinical Pathology, Cepheid, and Novartis AG First patients to receive treatment in Bahamas, Benin, Bhutan, Haiti, Jamaica, Mozambique,….
